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challenge in under-resourced health systems. Although the treatment
of eclampsia seems simple—introduce magnesium sulfate into the
woman’s blood stream and deliver the fetus as soon as possible—doing1. Background
Pre-eclampsia/eclampsia is a serious condition that complicates
5%–10% of pregnancies globally [1] and, together with other hyperten-
sive diseases of pregnancy, is responsible for approximately 14% of
maternal deaths every year [2]. Because treatment requires early and
careful monitoring of the pregnancy, the negative impact of these dis-
eases is felt more in low-income countries where health-system factors
often cause delay in reaching appropriate care [3]. In Nigeria, which has
the second highest number of maternal deaths in the world [4], the
prevalence of eclampsia/pre-eclampsia is reported at 163 per 10 000
deliveries [5]. One facility-based study [6] attributed 46.1% of maternal
deaths to pre-eclampsia and eclampsia in Jigawa state in Northern
Nigeria, where there is a high prevalence of early marriage (young age
is a risk factor for pre-eclampsia) [7].
Although there is little understanding of what causes pre-eclampsia/
eclampsia, there is an effective treatment for this condition. In 1994,
WHO recommended magnesium sulfate as the standard treatment for
pre-eclampsia and eclampsia, and within 2 years, it was placed on
WHO’s Essential Medicines List. Treatment of pre-eclampsia with
magnesium sulfate has been shown to signiﬁcantly lower the risk of
eclampsia (by 58%) and the risk of mortality (by 45%) [8–10].
Despite its known efﬁcacy, this inexpensive drug is often underused,
partly because the diffusion of an innovation takes time, but alsoe previously published by the
Sulfate for Treatment of Pre-
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logy and Obstetrics. Published byso in time and correctly is complicated and involves many steps and
many players [11–14].
The substantial contribution of pre-eclampsia/eclampsia tomaternal
mortality in Nigeria—along with the promise of magnesium sulfate
as a solution—caught the attention of the John D. and Catherine T.
MacArthur Foundation in 2005, when a program ofﬁcer overheard a
conversation between two Nigerian doctors who were lamenting the
failure of a piece of equipment in their hospital laboratory that was
used in the manufacture of magnesium sulfate. Without it, one was
saying to the other, they would have no supply of the drug to treat
pre-eclampsia/eclampsia and no way to save women’s lives.
In 2007, theMacArthur Foundation began funding a series of grants to
expand the use of magnesium sulfate for pre-eclampsia/eclampsia in
Nigeria. The impact of this work on maternal mortality was signiﬁcant:
the case fatality rate due to eclampsia dropped from 20.9% to 2.3%, and
the ﬁndings encouraged the government to scale up the intervention to
other states [15]. In 2014, the Foundation commissioned a process
evaluation of this work to help to determine what factors facilitated
uptake and expansion of magnesium sulfate services, the challenges
encounteredwhile implementing the projects, and existing opportunities
for future scaling up of the services across the country. The present paper
reports on the ﬁndings of that process evaluation.2. Methods
The process evaluationwas conducted by a teamof experts from the
Public Health Institute, Oakland, CA, USA, between June and November
2014. It included a desk review of literature and grantee reports, inter-
views with global experts and local key informants and stakeholders,
and visits to program sites. Most of the data were gathered using
qualitative methods: interviews with key stakeholders and evaluator
observations during site visits. Additionally, available quantitative data
were reviewed, with a focus on training records and hospital and health
center service statistics gathered by grantees. The Public Health
Institute’s institutional review board approved the research protocol
and interview guides before the researchwas performed (IRB# I14-012).Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
Fig. 1. The expansion in the number of states and facilities offering magnesium sulfate for
treatment of pre-eclampsia and eclampsia in Nigeria. Although all states had received
some level of training by 2010, the progress to scale up of services ranges from training
only in some states to integration into multiple hospitals in others.
234 S. Danmusa et al. / International Journal of Gynecology and Obstetrics 134 (2016) 233–2363. Overview of activities evaluated
Beginning in 2007, theMacArthur Foundationmade a series of grants
to both public (Federal Ministry of Health) and private organizations
(Population Council, Society of Gynaecology and Obstetrics of Nigeria
[SOGON], EngenderHealth, and Ipas) to integrate the use of magnesium
sulfate into the Nigerian health system. Recognizing that drug supply
alone would not guarantee successful access, the Foundation supported
a comprehensive set of activities that also included constituency building,
public advocacy, research and evaluation, and community outreach and
capacity building.
Work initially focused on drug supply, which was perceived to be
the biggest issue in Nigeria preventing use of magnesium sulfate. In
2007, the Foundation brought together stakeholders from the Federal
Ministry of Health and the United Nations Children’s Fund (UNICEF)
with an initial plan of using the well-established and secure UNICEF
supply chain to distribute magnesium sulfate and an ultimate goal
that state governments would put in place good and sustained procure-
ment, supply, and tracking policies to avoid stockouts and pilferages.
In 2008, an introductory pilot project in Kano State, Northern
Nigeria, trained doctors and midwives from 10 state health facilities to
administer magnesium sulfate using a simpliﬁed protocol (modiﬁed
Pritchard regimen). Concurrently, the project conducted community
sensitization efforts focused on helping women and their families to
identify the signs and symptoms of pre-eclampsia, and worked with
community health extension workers and traditional birth attendants
to address the need for recognition of the danger signs, treatment, and
referral. The substantial drop in mortality and the cost-effectiveness
of the magnesium sulfate intervention encouraged the Kano State
Government to scale up the intervention to the remaining 26 hospitals
in the state [15].
Building on the compelling evidence generated by the pilot project
in Kano, theMacArthur Foundation funded SOGON to expand the mag-
nesium sulfate work in Kano and to ﬁve other states (Plateau, Enugu,
Borno, Cross River, and Lagos), with a goal of introducing the drug in
one hospital in each state. SOGON engaged with state governments to
raise awareness and advocate for state policies, using its members to
visit health ofﬁcials throughout each of the designated states. Once
again, the substantial case fatality drop across the six state hospitals
(unpublished data) lent local legitimacy to the use of the drug to treat
pre-eclampsia and eclampsia. The snowball effect from these results
allowed for the scale-up and expansion of magnesium sulfate into
other states.
A 2008 grant enabled the FederalMinistry of Health to focus on insti-
tutionalizing delivery of magnesium sulfate throughout the healthcare
system, including development of national service delivery guidelines
and training curricula. The Ministry allied itself with the Nigerian
Medical Association and the National Association of Nigerian Nurses
and Midwives, as well as with obstetrics and gynecology department
heads and chief pharmacists of selected tertiary health institutions in
each state to integrate magnesium sulfate into existing clinical services.
The Ministry also conducted trainings—both in-service and pre-
service—in 170 institutions across all 36 states and the Federal Capital
Territory; through a process of step-down trainings, more than 1800
doctors were trained. Fig. 1 shows the incremental process to scale-up
of services.
As the expansion progressed, it became clear that efforts to initiate
treatment at the primary-care level were also needed; by the time
women reached the hospital, the condition had often progressed past
the point of effective treatment. A continuing grant to the Population
Council in 2011 enabled operations research in 20 primary-care
facilities—10 with a task-shifting intervention and 10 without the
intervention—to assess how best to involve traditional birth attendants,
community health extension workers, and nurses in identiﬁcation, im-
mediate clinical care, and referral. The work also involved ethnographic
research to determine the factors inﬂuencing the observed delay inwomen seeking treatment and to develop ways to facilitate more
successful referral for further care.
4. Findings
The Foundation’smultifaceted strategy enabled grantees to collective-
ly make substantial progress toward the full integration of the use of
magnesium sulfate into the Nigerian healthcare system. Of particular
note is that the Foundation and grantees incorporated recognized
strategies for successful scale-up [16] into project planning and
implementation. Fig. 2 provides an overview of how the speciﬁc
approaches used in Nigeria aligned with the recommended steps for
scale up. The evaluation ﬁndings support the use of this intentional
scale-up approach, particularly in the areas of building legitimacy
through the effective use of research and evaluation, strategically
engaging stakeholders to build a supportive constituency, andmodifying
structures (including task shifting, institutionalizing information and
training, and managing drug supply).
4.1. Using research and evaluation to legitimize change
The evaluation found that documenting and proving the utility and
success of magnesium sulfate was instrumental to the legitimization
of its use and the continued engagement of health ministries and
institutions. The rigorous research led by the Population Council helped
to seat the work within wider international evidence on the topic and
helped stakeholders to realize and understand the dynamics of the
complexities of administering the correct doses of magnesium sulfate,
and to recognize that midwives, nurses, and community health exten-
sion workers could safely administer the loading dose of the drug and
then provide accurate referral information and action.
4.2. Building a constituency
Diligent engagement with the government at every step of the pro-
gram combined with clinical successes helped to achieve the necessary
support, including at top levels of the government. The part played by
SOGON was judged by key informants as particularly important in the
legitimization of the intervention and gaining acceptance of the project
by government ofﬁcials at the national level; SOGON members and
other health professionals engaged by them became the loudest
advocates of magnesium sulfate to the government.
4.3. Task shifting and referral
The operations research that demonstrated successful task shifting
to include the community health extension workers in the administra-
tion of the treatment protocol was a key element of project success.
The Population Council’s research at the hospital and community level
showed that the women in need of the life-saving drug resided mostly
in rural areas, prompting a pilot study and program to train community
health extension workers to administer the ﬁrst loading dose and then
Fig. 2. Alignment of project approaches with steps in the scale-up process. Adapted from Cooley and Ved [14]. Abbreviation: SOGON, Society of Gynaecology and Obstetrics of Nigeria.
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health policies so that community health extension workers are now
allowed to administer the drug and refer cases for continued care. This
proved critical to better addressing the needs of rural women.
The evaluation identiﬁed two signiﬁcant problems with the referral
system. First, referral from primary healthcare facilities to magnesium
sulfate intervention sites was not timely, resulting in deaths at the
referral site (it was noted that most fatal cases of eclampsia were
those referred from the primary healthcare level). Because most
primary healthcare facilities have not beneﬁted from the intervention
and scale-up efforts, major problems remain in terms of timing and
effectiveness of referral from these locations.
Second, stakeholders reported that many patients who received a
loading dose failed to complete the referral process to a higher level
facility for delivery. This ﬁnding is consistent with other studies: in
one study [17], 90% of women who received the loading dose did not
complete the referral process.
4.4. Developing guidelines, curricula, and job aides
The development of national service delivery guidelines and training
curricula for the use of magnesium sulfate to treat pre-eclampsia and
eclampsia, and their subsequent integration into the national healthcare
system, was found to be another key factor supporting scale-up efforts.
Clear protocols (including guidelines and algorithms for the administra-
tion of magnesium sulfate) for training of all levels of service providers
(including community health extension workers) were collaboratively
produced by the Federal Ministry of Health, EngenderHealth, the
Population Council, SOGON, State Health Commissioners, and other
partner organizations. With the assistance of state-level actors and
community stakeholders, these protocols permeated down to local
government areas, including at the health facility and community levels.
Job aides helped to solidify correct practice.
Nevertheless, continuing the advocacy and engagement with
policymakers as well as with new medical and nursing staff will be
critical to build on the achievements and maintain the momentum
that has been developed. The evaluation found that full integration of
magnesium sulfate into the curricula and standards of care in Nigeria
is still very vulnerable. One stakeholder commented: “Within just few
months of its introduction,mortality fromeclampsia fell to zero in all in-
tervention facilities. However, after [the pilot], mortality from eclampsia
returned to its pre-pilot period in all the facilities. It was then werealized how important advocacy is to the introduction of a drug or
service, nomatter how good it is. If we had done good advocacy, the gov-
ernmentwould have taken over andwemay not have had a return to the
pre-magnesium sulfate period in terms of mortality from eclampsia in
those facilities.”
4.5. Addressing drug supply issues
The evaluation found that the Population Council’s focus on effective
monitoring, requisitioning, and distribution of drugs at program
facilities is beginning to address magnesium sulfate supply problems
in Nigeria. Key informants noted that the enhanced monitoring of
magnesium sulfate supplies had a positive effect on reducing stockouts
not only of magnesium sulfate, but also of other medicines. In Kano
State, the increased focus on effective monitoring, requisitioning, and
distribution of drugs at engaged facilities and at the administrative
level was believed to have positively affected other aspects of the
health system.
The general state of the government’s free maternal health medical
services program—whichwas designed to improve access to health ser-
vices including essential health commodities—was, however, frequently
mentioned by informants as a key reason why the government’s
magnesium sulfate scale up has not been fully realized. This is because
the supply of magnesium sulfate as part of the free medical services is
now being affected by the irregularity of the free medical supplies.
Most informants did not freely admit to lack ofmagnesium sulfate in
the facilities where they work. However, many service providers
interviewed maintained that the reason magnesium sulfate supply
was never exhausted at the general hospitals was because health
workers in the hospitals would only provide the loading dose of the
drug, requiring patients to purchase the additional doses needed for
treatment from the private sector (magnesium sulfate appears to be
readily available through hospital pharmacies). According to one
study conducted in 2013 [17], 62.2% of the cases required families of
the women to purchase the drug for use after the loading dose.
5. Discussion
By successfully implementing theMacArthur Foundation’s multifac-
eted strategy and paying attention to the necessary steps in the scale-up
process, grantees have collectively made substantial progress toward
the full integration of the use of magnesium sulfate into the Nigerian
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gone from sporadic use by a handful of providers to use in more than
400 of Nigeria’s 1042 secondary and tertiary hospitals across the
country. This transition is particularly remarkable given the general
challenges faced by the health infrastructure in Nigeria and the fact
that magnesium sulfate involves a complicated clinical protocol.
Numerous challenges still remain as the country continues to scale
up the program. Correct use of magnesium sulfate is very inconsistent
and there is the need to address the underlying factors that prevent
health workers from providing magnesium sulfate according to accept-
able standards. These factors include: continued provider hesitancy
about the complexity of the dosing protocol; inadequate number of
trained staff as a result of transfers, retirements, and attrition;
inadequate drug supply; and failure to follow the protocol to refer
and/or deliver the pregnancy (sometimes even sending the woman
home), mainly because of the misperception that the loading dose of
magnesium sulfate (which effectively stops convulsions) has treated
the problem.
Continued monitoring will be important to ensure that the new
guidelines and curricula are included in the training of all new
healthcare workers. Although work with the regulatory agencies at
the national level and selected training institutions has provided
evidence of workability, there is a critical need to include magnesium
sulfate in the curricula of all institutions that train midwives and
community health extension workers. Until the curricula are viewed
as integral to medical and nursing training, monitoring and advocacy
will be required.
There is also an ongoing need for community-based education on
the symptoms of pre-eclampsia/eclampsia and on the importance of
medical care even beyond the initial relief of the loading dose ofmagne-
sium sulfate. The rates of institutional births and births attended by a
skilled birth attendant are still low throughout Nigeria and especially
in the north [7]. Because the full regimen of magnesium sulfate must
be completed at the hospital level, channels must be explored to ensure
a continuum of care from home to hospital. Practical ways to improve
the effectiveness of the home-to-hospital continuum of care include:
helping households to identify the danger signs of pregnancy and
understand need for referral through training of community resource
persons (e.g. traditional birth attendants) and by involvingwomen’s ad-
vocacy groups in the community; capitalizing on the recent policy
changes on task shifting to devolve the administration of the loading
dose of magnesium sulfate to the community health extension workers
at primary health centers; helping communities to solve their referral
transport challenges; improving the quality of prenatal care services
by ensuring that needed supplies are available and using a checklist
that will help improve the detection of pre-eclampsia at prenatal care
visits; and improving the quality of the care women receive in the
health facilities so they will trust the services and not avoid using them.
Mistrust of health services, and of hospitals particularly, poses an al-
most insurmountable barrier to reducing the risk of eclampsia. A model
that recognizes the pregnant woman as a consumer who will make
choices on the basis of personal, societal, and structural inﬂuences can
help to identify barriers and suggest possible interventions. Enlisting
the support of women’s advocacy groups to generate demand for qual-
itymaternal health serviceswhile improving the quality of the interper-
sonal care provided in facilities will help to build trust in the delivery
services. Generating a public demand for woman-friendly delivery ser-
vices is an approach that could be conducive in Nigeria, given the pre-
dominance and strength of women’s advocacy groups in the country.
6. Conclusion
The story of how Nigeria introduced and scaled up use of magne-
sium sulfate to treat eclampsia—one of its most prevalent causes of
maternal mortality—can provide important information and insight to
other countries struggling with the same problem. The MacArthurFoundation led this scale-up by bringing together and supporting a
complementary groupof players to implement amultifaceted approach.
The approach recognized that incorporating a new clinical practice into
a healthcare system takes careful planning, policy support, resources,
and time. Through sustained funding, and by paying attention to all
the components necessary for the scale-up of a new technology such
as magnesium sulfate, the MacArthur Foundation and the Federal
Ministry of Health of Nigeria, working in concert with professional soci-
eties and key research institutions, have demonstrated a successful path
to expanding access to this lifesaving treatment that can be adapted and
replicated in other countries.Acknowledgments
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